EMA Recommends Approval of Vyjuvek

Research
Written By Dan McKernan

A major milestone in the fight against Epidermolysis Bullosa brings new hope to patients worldwide

Groundbreaking Approval Recommendation

Exciting news for the EB community! The European Medicines Agency (EMA) has recommended approval for Vyjuvek, the first-ever topical gene therapy developed specifically to heal chronic wounds in patients with Dystrophic Epidermolysis Bullosa (DEB).

This innovative treatment represents a significant advancement in EB care, targeting the root cause of the disease by directly delivering the missing collagen to wounds. Clinical trials have demonstrated remarkable efficacy, with 67% of patients experiencing wound healing after just 6 months of treatment.

A Milestone in EB Research

At EB Research Partnership, we've been at the forefront of funding critical research and accelerating treatments like Vyjuvek to help those suffering from this debilitating condition. This development brings tremendous hope to the DEB community worldwide.

However, our work is far from complete. While this recommendation marks a crucial step forward, Vyjuvek is not yet widely available globally and could take years to reach patients in many countries without coordinated action.

Our Commitment to Global Access

We remain steadfastly committed to funding vigorous research efforts to accelerate global access to this life-changing treatment. Every person living with EB deserves access to the most effective treatments available, regardless of where they live.

Your continued support of EB Research Partnership makes this vital work possible. Together, we can help bring revolutionary treatments like Vyjuvek to EB patients worldwide in months rather than years.

Join Our Mission

This breakthrough demonstrates what's possible when dedicated researchers, supportive communities, and organizations like ours work together toward a common goal. With your help, we can continue pushing the boundaries of what's possible in EB treatment.

Thank you for standing with us as we push for faster access to breakthrough treatments for the EB community worldwide!

To learn more about our work or to support our mission, visit EB Research Partnership today.

Follow us on social media for the latest updates on EB research and treatments:

Dan McKernan